<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614180</url>
  </required_header>
  <id_info>
    <org_study_id>KS2022056</org_study_id>
    <nct_id>NCT05614180</nct_id>
  </id_info>
  <brief_title>Chronic Total Occlusive Lesions CMR Study</brief_title>
  <acronym>CTO-CMR</acronym>
  <official_title>Chronic Total Occlusive Lesions CMR Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lin Zhao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This registry will include consecutive patients presenting with at least one chronic total&#xD;
      occlusion on coronary angiogram who will be treated by percutaneous coronary intervention in&#xD;
      our center. All patients will undergo a non-invasive assessment for myocardial&#xD;
      ischemia/viability using cardiac magnetic resonance (CMR) prior to revascularization therapy.&#xD;
      Follow up CMR will be repeated in all participants after three months and one year.&#xD;
      Additionally, clinical outcomes and quality of life will be evaluated at baseline and at&#xD;
      follow-up. Primary objective of this study is to investigate the the reduction in ischemia&#xD;
      (as evaluated by follow-up CMR) and the severity of angina according to clinical evaluation&#xD;
      (including Seattle Angina Questionnaires [SAQ], Canadian Class Score[CCS] and 6-mins walking&#xD;
      test).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">January 20, 2023</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ischemia</measure>
    <time_frame>3 months; 12 months</time_frame>
    <description>Parameters of cardiac magnetic resonance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of target lesion failure (TLF).</measure>
    <time_frame>12 months</time_frame>
    <description>TLF is defined as a composite of: cardiac death, target vessel myocardial infarction (SCAI definition), and clinically driven TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in angina paramteres</measure>
    <time_frame>3 months; 12 months</time_frame>
    <description>Parameters of angina questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of left ventricular structure and function</measure>
    <time_frame>3 months; 12 months</time_frame>
    <description>Parameters of left ventricular function and structure on cardiac magnetic resonance</description>
  </secondary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Chronic Total Occlusion</condition>
  <condition>Image</condition>
  <condition>Revascularization</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>Patients with a diagnose of coronary chronic total occlusions will be treated by percutaneous coronary intervention, as indicated by the heart-team.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes patients presenting with a diagnose of coronary chronic total&#xD;
        occlusions undergoing percutaneous coronary intervention.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Presence of at least one untreated CTO at basal angiography (defined as a total&#xD;
             occlusion in any major coronary vessel or relevant side branches [reference vessel&#xD;
             diameter â‰¥2.5mm or as judged by two independent interventional cardiologists], with&#xD;
             TIMI 0 in the distal segment and at least 3 months old&#xD;
&#xD;
          -  Patient has a clinical indication to perform CTO PCI&#xD;
&#xD;
          -  Willing to participate and able to understand, read and sign the informed consent&#xD;
             document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CMR contraindications&#xD;
&#xD;
          -  Contraindications to adenosine or dobutamine&#xD;
&#xD;
          -  Severe chronic kidney disease (estimated Glomerular Filtration Rate [eGFR] &lt;60&#xD;
             mL/min/1.73m2 or serum creatinine level &gt;2.5 mg/dL)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Zhao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Anzhen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xu Wang, MD</last_name>
    <phone>+8615311765609</phone>
    <email>huaianwangxu@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing anzhen hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Wang</last_name>
      <phone>+86 15311765609</phone>
      <email>huaianwangxu@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>November 5, 2022</study_first_submitted>
  <study_first_submitted_qc>November 5, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>January 16, 2023</last_update_submitted>
  <last_update_submitted_qc>January 16, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Lin Zhao</investigator_full_name>
    <investigator_title>Associate director of cardiology department</investigator_title>
  </responsible_party>
  <keyword>Chronic Total Occlusion</keyword>
  <keyword>Cardiac magnetic resonance</keyword>
  <keyword>Revascularization</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

